Funding
Funding not disclosed
Founders
Product
Problem
Autoimmune diseases are characterized by an overactive or misdirected immune response that attacks the body's own tissues. Current therapeutic modalities primarily focus on broad immune suppression, which can lead to significant side effects and does not address the underlying loss of immune tolerance. This approach often manages symptoms rather than achieving disease remission or reversal.
Solution
Ananda Immunotherapies is developing a novel class of immunotherapies designed to restore immune tolerance and reverse autoimmune conditions. The company's platform leverages the inherent regulatory functions of T regulatory cells (Tregs) to re-establish immune homeostasis. By precisely modulating the immune system's network of interactions, rather than broadly suppressing it, Ananda's therapies aim to correct the root cause of autoimmunity. This approach has the potential to achieve durable disease remission and potentially cure autoimmune diseases. The company is advancing a pipeline of Treg-based candidates targeting various autoimmune indications.
Target Audience
Ananda Immunotherapies targets patients with autoimmune diseases and the healthcare providers who treat them, including rheumatologists, immunologists, and clinical researchers.
Features
- Next-generation immunotherapies focused on restoring immune tolerance.
- Proprietary platform utilizing regulatory T-cells (Tregs) to rebalance the immune system.
- Mechanism of action targets the underlying loss of immune tolerance, not just symptom suppression.
- Potential for disease reversal and durable remission in autoimmune conditions.
- Pipeline of Treg-based therapeutic candidates for multiple autoimmune diseases.